drugset
drugset / Trial / NCT03967964

Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)

NCT03967964 ↗

Phase 1 Completed 46 enrolled Laboratorios Andromaco S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was performed to determine the pharmacokinetic parameters of vaginal rings that contain DHEA, testosterone, or combinations of both androgens, in comparison to the oral administration of DHEA and the transdermal administration of testosterone.

Timeline

Start
2015-11-20
Primary completion
2016-07-15
Completion
2016-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified 25 mg Other
Subject Dehydroepiandrosterone Other / unclassified 1.5 g Other
Subject Dehydroepiandrosterone Other / unclassified 2.2 g Other
Subject Testosterone Small molecule 15 mg Other
Subject Testosterone Small molecule 25 mg Other
Subject Testosterone Small molecule 35 mg Other

Indications

No indication recorded.